Pfizer Inc. and French biotech company Valneva SE are launching a phase 3 clinical study to test an experimental vaccine against Lyme disease, the companies announced on Aug. 8.
Lyme disease is the most common vector-borne disease in the United States and is caused by the Borrelia burgdorferi bacteria. It is transmitted to humans through the bite of infected black-legged ticks, also called deer ticks.
